MX350011B - Composiciones terapeuticas que contienen macitentan. - Google Patents

Composiciones terapeuticas que contienen macitentan.

Info

Publication number
MX350011B
MX350011B MX2011001625A MX2011001625A MX350011B MX 350011 B MX350011 B MX 350011B MX 2011001625 A MX2011001625 A MX 2011001625A MX 2011001625 A MX2011001625 A MX 2011001625A MX 350011 B MX350011 B MX 350011B
Authority
MX
Mexico
Prior art keywords
compositions containing
therapeutic compositions
compound
containing macitentan
macitentan
Prior art date
Application number
MX2011001625A
Other languages
English (en)
Other versions
MX2011001625A (es
Inventor
Clozel Martine
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41346591&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX350011(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of MX2011001625A publication Critical patent/MX2011001625A/es
Publication of MX350011B publication Critical patent/MX350011B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5578—Eicosanoids, e.g. leukotrienes or prostaglandins having a pentalene ring system, e.g. carbacyclin, iloprost
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Esta invención se relaciona con un producto que contiene un compuesto de fórmula (I) a continuación (Ver fórmula (I)) o una sal farmacéuticamente aceptable de este compuesto, en combinación con al menos un compuesto que tiene propiedades de agonista del receptor prostaciclina (IP), o una sal farmacéuticamente aceptable del mismo.
MX2011001625A 2008-08-13 2009-08-12 Composiciones terapeuticas que contienen macitentan. MX350011B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB2008053252 2008-08-13
PCT/IB2009/053553 WO2010018549A2 (en) 2008-08-13 2009-08-12 Therapeutic compositions containing macitentan

Publications (2)

Publication Number Publication Date
MX2011001625A MX2011001625A (es) 2011-03-29
MX350011B true MX350011B (es) 2017-08-22

Family

ID=41346591

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011001625A MX350011B (es) 2008-08-13 2009-08-12 Composiciones terapeuticas que contienen macitentan.

Country Status (29)

Country Link
US (3) US8809334B2 (es)
EP (2) EP3300729B1 (es)
JP (3) JP5764061B2 (es)
KR (1) KR101678699B1 (es)
CN (1) CN102099026B (es)
AR (1) AR073031A1 (es)
AU (1) AU2009280843B2 (es)
BR (1) BRPI0917661B8 (es)
CA (1) CA2731370C (es)
CY (2) CY1119826T1 (es)
DK (2) DK3300729T3 (es)
ES (2) ES2652590T3 (es)
HK (1) HK1253355B (es)
HR (2) HRP20171917T1 (es)
HU (2) HUE036071T2 (es)
IL (1) IL211143A0 (es)
LT (2) LT3300729T (es)
MA (1) MA32614B1 (es)
MX (1) MX350011B (es)
MY (1) MY178894A (es)
NO (1) NO2315587T3 (es)
NZ (1) NZ591601A (es)
PL (2) PL2315587T3 (es)
PT (2) PT3300729T (es)
RU (1) RU2519161C2 (es)
SI (2) SI3300729T1 (es)
TW (1) TWI446911B (es)
WO (1) WO2010018549A2 (es)
ZA (1) ZA201101900B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1928409T1 (sl) 2005-09-12 2012-12-31 Actelion Pharmaceuticals Ltd. Stabilni farmacevtski sestavek, ki obsega pirimidin-sulfamid
MX2010001837A (es) 2007-08-17 2010-03-10 Actelion Pharmaceuticals Ltd Derivados de 4-pirimidinasulfamida.
CN104761509A (zh) 2008-02-28 2015-07-08 日本新药株式会社 纤维化抑制剂
TWI446911B (zh) 2008-08-13 2014-08-01 Actelion Pharmaceuticals Ltd 含美西特田（ｍａｃｉｔｅｎｔａｎ）之治療組合物
EP3712142B1 (en) 2013-01-11 2022-07-06 Corsair Pharma, Inc. Prodrugs of treprostinil
US9505737B2 (en) 2013-01-11 2016-11-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
US9394227B1 (en) 2015-06-17 2016-07-19 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US9643911B2 (en) 2015-06-17 2017-05-09 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US9794795B1 (en) 2016-04-29 2017-10-17 Corning Optical Communications Wireless Ltd Implementing a live distributed antenna system (DAS) configuration from a virtual DAS design using an original equipment manufacturer (OEM) specific software system in a DAS
US10912778B2 (en) 2016-12-14 2021-02-09 Respira Therapeutics, Inc. Methods for treatment of pulmonary hypertension
CN112672746A (zh) * 2018-09-14 2021-04-16 国邑药品科技股份有限公司 用于控制释放弱酸药物的医药组合物及其用途
MX2021007455A (es) * 2018-12-21 2021-08-05 Actelion Pharmaceuticals Ltd Composicion farmaceutica para el tratamiento de hipertension arterial pulmonar.
TW202042818A (zh) 2019-01-25 2020-12-01 瑞士商艾克泰聯製藥有限公司 用於治療慢性血栓性肺高血壓之醫藥組成物
AU2020408323A1 (en) 2019-12-16 2022-08-11 Tenax Therapeutics, Inc. Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HF-pEF)

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4539333A (en) * 1976-05-11 1985-09-03 Burroughs Wellcome Co. Prostacyclin, methods of using and method of making
DE2845770A1 (de) * 1978-10-19 1980-04-30 Schering Ag Neue prostacyclin-derivate und verfahren zu ihrer herstellung
JPS58124778A (ja) 1982-01-20 1983-07-25 Toray Ind Inc ５，６，７−トリノル−４，８−インタ−ｍ−フエニレンＰＧＩ↓２誘導体
US4683330A (en) * 1984-03-08 1987-07-28 The Upjohn Company Interphenylene carbacyclin derivatives
NZ525614A (en) 2000-12-18 2005-03-24 Actelion Pharmaceuticals Ltd Novel sulfamides and their use as endothelin receptor antagonists
SK8192003A3 (en) * 2000-12-19 2003-10-07 Merck Patent Gmbh Pharmaceutical formulation containing pyrazolo[4,3-d]pyrimidines and antithrombotic agents, calcium-antagonists, prostaglandins or prostaglandin derivatives
DE10100426B4 (de) 2001-01-08 2006-04-06 Steag Hamatech Ag Verfahren und Vorrichtung zum Zusammenfügen von Substraten
TWI316055B (es) * 2001-04-26 2009-10-21 Nippon Shinyaku Co Ltd
WO2004017993A1 (en) * 2002-08-12 2004-03-04 Actelion Pharmaceuticals Ltd Combination of prostacyclin or prostacyclin analogues and endothelin receptor antagonists for the treatment of pulmonary arterial hypertension
RU2329255C2 (ru) * 2002-12-02 2008-07-20 Актелион Фармасьютиклз Лтд Пиримидинсульфамиды и их использование в качестве антагонистов эндотелиальных рецепторов
US20050101608A1 (en) * 2003-09-24 2005-05-12 Santel Donald J. Iloprost in combination therapies for the treatment of pulmonary arterial hypertension
TW200628467A (en) * 2004-11-11 2006-08-16 Actelion Pharmaceuticals Ltd Novel sulfamides
SI1928409T1 (sl) 2005-09-12 2012-12-31 Actelion Pharmaceuticals Ltd. Stabilni farmacevtski sestavek, ki obsega pirimidin-sulfamid
AR062501A1 (es) 2006-08-29 2008-11-12 Actelion Pharmaceuticals Ltd Composiciones terapeuticas
KR20100132489A (ko) * 2008-02-20 2010-12-17 액테리온 파마슈티칼 리미티드 난소암을 치료하기 위하여 파클리탁셀을 포함하는 조합
TWI446911B (zh) 2008-08-13 2014-08-01 Actelion Pharmaceuticals Ltd 含美西特田（ｍａｃｉｔｅｎｔａｎ）之治療組合物

Also Published As

Publication number Publication date
MY178894A (en) 2020-10-21
US8809334B2 (en) 2014-08-19
EP2315587A2 (en) 2011-05-04
JP5956025B2 (ja) 2016-07-20
NZ591601A (en) 2012-12-21
HRP20192204T1 (hr) 2020-03-06
NO2315587T3 (es) 2018-03-24
AR073031A1 (es) 2010-10-06
PT2315587T (pt) 2018-01-31
HUE047767T2 (hu) 2020-05-28
TW201010985A (en) 2010-03-16
CN102099026B (zh) 2012-08-29
EP3300729A1 (en) 2018-04-04
US9597331B2 (en) 2017-03-21
WO2010018549A2 (en) 2010-02-18
BRPI0917661B8 (pt) 2021-05-25
EP2315587B1 (en) 2017-10-25
US9173881B2 (en) 2015-11-03
BRPI0917661A2 (pt) 2015-12-01
CY1119826T1 (el) 2018-06-27
RU2011109084A (ru) 2012-09-20
ES2763176T3 (es) 2020-05-27
CA2731370A1 (en) 2010-02-18
DK3300729T3 (da) 2020-01-20
JP2015180683A (ja) 2015-10-15
US20140329824A1 (en) 2014-11-06
US20110136818A1 (en) 2011-06-09
AU2009280843B2 (en) 2015-03-05
SI2315587T1 (en) 2018-04-30
IL211143A0 (en) 2011-04-28
HRP20171917T1 (hr) 2018-02-09
PL3300729T3 (pl) 2020-04-30
KR20110045006A (ko) 2011-05-03
KR101678699B1 (ko) 2016-11-23
SI3300729T1 (sl) 2020-02-28
DK2315587T3 (en) 2018-01-02
JP2015187148A (ja) 2015-10-29
HK1253355A1 (zh) 2019-06-14
JP2011530581A (ja) 2011-12-22
MX2011001625A (es) 2011-03-29
US20160022678A1 (en) 2016-01-28
TWI446911B (zh) 2014-08-01
JP5956026B2 (ja) 2016-07-20
ZA201101900B (en) 2012-08-29
LT3300729T (lt) 2020-01-10
LT2315587T (lt) 2018-01-10
HUE036071T2 (hu) 2018-06-28
RU2519161C2 (ru) 2014-06-10
EP3300729B1 (en) 2019-10-09
PL2315587T3 (pl) 2018-03-30
HK1253355B (zh) 2020-06-19
AU2009280843A1 (en) 2010-02-18
CN102099026A (zh) 2011-06-15
JP5764061B2 (ja) 2015-08-12
CA2731370C (en) 2017-03-14
PT3300729T (pt) 2020-01-20
CY1122641T1 (el) 2021-03-12
ES2652590T3 (es) 2018-02-05
MA32614B1 (fr) 2011-09-01
BRPI0917661B1 (pt) 2019-12-17
WO2010018549A3 (en) 2010-07-29

Similar Documents

Publication Publication Date Title
MY178894A (en) Therapeutic compositions containing macitentan
UA94833C2 (en) Substituted bicyclolactams
MY146924A (en) Substituted imidazoheterocycles
WO2008021849A3 (en) Novel compounds as antagonists or inverse agonists at opioid receptors
MX2012003389A (es) Moduladores de gpr40 de pirrolidina.
TN2011000222A1 (en) Melanocortin receptor agonists
WO2012030927A3 (en) Modified-release dosage forms of 5-ht2c agonists useful for weight management
TW200612958A (en) Substituted imidazole derivatives
UA92670C2 (ru) Пиразолиновые соединения и их фармацевтическое применение, композиция на их основе
MX2010008993A (es) Derivados de 2-aza-biciclo-[2.2.1]heptano.
TW200833328A (en) 2-aza-bicyclo[3.1.0]hexane derivatives
MX2009007077A (es) Analogos de ciclopamina.
PT2421879E (pt) Novos 7-deazapurina nucleósidos para utilizações terapêuticas
HK1158192A1 (en) Piperidine gpcr agonists
MX2008013196A (es) 5-amido-2-carboxiamida-indoles.
TN2009000287A1 (en) Cyclized derivatives as eg-5inhibitors
PT2310356E (pt) Derivados de adamantildiamida e a sua utilização
MX353209B (es) Antagonistas d2, metodos de sintesis y metodos de uso.
GB0812642D0 (en) Compounds
MX2009010552A (es) Antagonistas de receptor de opioide periferico y usos de los mismos.
TW200942524A (en) Novel aminomethyl benzene derivatives
MY147188A (en) Substituted imidazole compounds as ksp inhibitors
MX2009008028A (es) Agentes antiparasitarios.
EP2238105A4 (en) NOVEL COMPOUNDS, ISOMERS, OR PHARMACEUTICAL ACCEPTABLE SALTS THEREOF, CONTAINING VANILLOID RECEPTOR ANTAGONISTS, AND PHARMACEUTICAL COMPOSITIONS THEREWITH
MY161749A (en) Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use

Legal Events

Date Code Title Description
FG Grant or registration